Navigation Links
The Leukemia & Lymphoma Society Applauds FDA's Approval of Lenalidomide for Patients with Relapsed or Refractory Mantle Cell Lymphoma
Date:6/5/2013

WHITE PLAINS, N.Y., June 5, 2013 /PRNewswire/ -- Today's U.S. Food and Drug Administration (FDA) approval of lenalidomide (Revlimid®) to treat patients with mantle cell lymphoma (MCL) is encouraging news for these patients.

"Despite advances in treatment, most mantle cell lymphoma patients relapse over time. So, lenalidomide is a welcome effective treatment option for these patients," said Clare Karten , senior director of mission education for The Leukemia & Lymphoma Society (LLS).

The approved indication is for MCL patients whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib (Velcade ®). This also marks the first oral therapy for patients with MCL.

Lenalidomide was originally approved by the FDA in 2006 to treatment patients with multiple myeloma who had undergone at least one prior treatment. The FDA approved lenalidomide in 2006 for a certain subset of patients with myelodysplastic syndromes (MDS).

Many LLS-funded researchers have helped advance lenalidomide by testing its effectiveness for patients with myeloma and MDS, as well as patients diagnosed with non-Hodgkin lymphoma and chronic lymphocytic leukemia, both alone and in various combinations with other therapies.

LLS is also pleased to announce that it will be hosting an education program on treatment options for mantle cell lymphoma on June 26, 2013, from 1-2 p.m. ET. John P. Leonard , M.D., of Weill Cornell Medical Center, will be the featured speaker. Click here to register for this program or visit this link: http://www.cancereducation.com/cancersyspagesnb/a/lls/lls1303/index.html

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.  

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

Contact: Andrea Greif
914-821-8958
andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
2. Leading Leukemia Experts: High Leukemia Treatment Costs May Be Harming Patients
3. Tosedostat OPAL Study in Acute Myeloid Leukemia Published in Lancet Oncology
4. Launch Of Premium-priced, Novel Targeted Therapies Will Drive Growth In The Acute Leukemia Markets Beginning In 2015
5. The Leukemia & Lymphoma Society and Avella Specialty Pharmacy to Present Free Event on Oral Chemotherapy Drugs
6. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
7. Burlington Coat Factory Completes Another Record Year of Supporting The Leukemia & Lymphoma Society in its Quest to Beat Cancer
8. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
9. Constellation Pharmaceuticals and The Leukemia & Lymphoma Society Partner to Develop Novel BET Inhibitor for the Treatment of Hematologic Malignancies
10. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
11. Actinium Pharmaceuticals Announces The Addition of The Fred Hutchinson Cancer Research Center To Actiniums Multicenter Clinical Trial For Patients With Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Now in its seventh year, the Pharmaceutical Innovation ... at developing and commercialising innovation. ... The Index can be summarised by ... different companies in early phase, which would make the best ... each company,s performance between 2011 and 2016, the 2017 ranking sees the ...
(Date:2/27/2017)... Leading Countries, Technologies and Companies ... grow at a CAGR of 8.9% from 2016-2021 and CAGR of ... CAGR of 9.1% from 2016 to 2027. The market is estimated ... ... Read on to discover how you can exploit the future ...
(Date:2/27/2017)... and PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI), a leading developer of adult stem ... of June S. Almenoff , M.D., Ph.D., FACP, ... its Board of Directors.  "Dr. Almenoff ... whose appointments come at an exciting time for our ...
Breaking Medicine Technology:
(Date:2/28/2017)... (PRWEB) , ... February 28, 2017 , ... ... March 7, 2017, from 4:30-5:30 p.m. at the 11th Annual RISE Nashville Summit. ... management, financial compliance, performance analytics, and engagement strategies. , The discussion will include ...
(Date:2/27/2017)... ... February 27, 2017 , ... It’s no secret ... often leads to a host of health issues, including urinary incontinence. However, results ... discovered that good overall muscle strength in older women, particularly in the ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... Robert E. ... large medical group. But his impoverished upbringing and life experiences could have led him ... a Physician: Insightful and Inspirational Tales of Parenting, Perseverance and Pediatrics,” Dr. Burke shares ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... Much attention ... concern for women who become dependent on opioid painkillers has fallen short. From 1999 ... compared to a 237% increase in fatal overdoses in male populations.(1) , The proportion ...
(Date:2/27/2017)... ... February 27, 2017 , ... Elisa Guajardo Carothers is not your typical author. She went from ... a nun. Now, she writes about God, when she isn’t swimming as a performing mermaid. ... Here is BS! (Before Satan),” she offers a comedic look at the dysfunctions of God’s ...
Breaking Medicine News(10 mins):